

- Libby Ferguson libby.ferguson@mariecurie.org.uk
- Jude Marshall
- judithmarshall@nhs.net

Topics

- Experience so far
- Where are people dying from COVID 19 in Glasgow?
- Symptom control and anticipatory prescribing
- Syringe drivers and contingency plans for alternatives
- Communication tc and vc
- ACP in care homes
- Oxygen
- Support available

COVID Deaths GG&C NRS 3/6/20

	COVID	All cause
Home	57	2005
Care Home	589	2103
Hospital	612	2828
Other institution	4	17

End of Life Care Guidance when a Person is Imminently Dying from COVID-19 Lung Disease

The focus of this guideline is to reduce the suffering for those dying from COVID-19 lung disease.

- A proportion of patients dying of COVID-19 lung disease could have severe symptoms with rapid decline. In this situation it is important to deliver effective medications, at effective doses, from the outset. Early management of symptoms will be the most effective way to reduce suffering.
- The clinical profile of COVID-19 lung disease driven dying is likely to include:
- · High breathlessness / 'air hunger'
- High distress
- High delirium / agitation
- High fever
- Risk of cessation of life over a short number of hours.

This guideline should only be used when reversible causes for deterioration have been addressed and there is consensus that the patient is dying.

Atypical presentations

- Less likely to present with cough, breathlessness or temperature
- Delirium
- Anorexia, fatigue, malaise
- Gl symptoms
- Deterioration in function
- Falls/ syncope
- Day to day variability



https://www.palliativecareguidelines.scot.nhs.uk/guidelines/symptom-control/end-of-life-careguidance-when-a-person-is-imminently-dying-from-covid-19-lung-disease.aspx

Breathlessness

Consider whether the patient is benefiting from any oxygen prescribed. If not, consider discontinuing non-beneficial oxygen and using medication and non-pharmacological measures for symptom control.

Patients who are receiving medication via nebulisers may continue to do so in the context of COVID-19 lung disease. Currently corticosteroids are not recommended for managing the symptoms of dying of COVID-19 lung disease.

Non-pharmacological measures to manage breathlessness should also be considered, these include positioning, relaxation techniques, wiping the face with cool wipes.

Fans must not be used in the context of COVID-19 infection as they increase aerosol spread of the virus.

Morphine sulfate	Subcutaneous or slow intravenous injection	Start with 2 to 5mg as required; can be titrated to resolution of symptoms.			
	Subcutaneous infusion	Start with 10 to 20mg over 24h.			
Midazolam	Subcutaneous or slow intravenous injection	Start with 2 to 5mg as required; can be titrate resolution of symptom	•Consider using the patient is very breathlessness.	 Consider using the higher dose the patient is very distressed wi 	
	Subcutaneous infusion	Start with 10 to 20mg 24h.	elderly patients. •Maximum dose 100mg over 2		

Cough

Morphine sulfate	Oral	5mg every hour as required	Consider using lower doses in elderly patients.In patients who are already receiving	
	Subcut injection	2mg every hour as required	regular opioid, use 1/6 of total daily opioid dose for as required dose.	
	Subcut infusion	10 to 20mg over 24h		
Codeine linctus	Oral	60mg every 6 hours as required		

If the patient has known renal impairment (eGFR <30), consider using equivalent and equipotent doses of oxycodone, if immediately available, as required and alfentanil or oxycodone in an infusion. Refer to:

https://www.palliativecareguidelines.scot.nhs.uk/guidelines/pain/choosing-and-changing-opioids.aspx for conversions. If only one opioid is available, this should be used to relieve suffering in the setting of COVID-19 lung disease rapid dying.

Hyoscine Butylbromide	Subcutaneous injection	20mg every hour as required
	Subcutaneous infusion	Up to 180mg over 24h
Glycopyrronium	Subcutaneous injection	200micrograms every hour as required
	Subcutaneous infusion	1.2mg over 24h
Hyoscine Hydrobromide	Subcutaneous injection	400micrograms every hour as required
	Subcutaneous infusion	2.4mg over 24h

 Alternative drugs and routes of administration are also available -Refer to: https://www.pa lliativecareguidelin es.scot.nhs.uk/guid elines/symptomcontrol/alternative s-to-regularmedicationnormally-given-viaa-syringe-pumpwhen-this-is-notavailable.aspx

Respiratory secretions

Terminal delirium / Terminal agitation / Terminal restlessness

A combination of midazolam and levomepromazine should be considered in terminal agitation/restlessness/delirium.

Early commencement of syringe pump, if available, is strongly recommended.

Midazolam	Subcutaneous or slow intravenous injection	Start with 2 to 5mg as required; can be titrated to resolution of symptoms.	 Titration frequency: subcutaneous 10- 15mins; intravenous 3-5mins. Maximum dose 100mg over 24h. Better for agitation due to distress and anxiety.
	Subcutaneous infusion	Start with 10 to 20mg over 24h	 Consider using lower doses in elderly patients. High doses may be required in patients who have severe agitation.
ir S	Subcutaneous injection	Start with 10 to 25mg every hour as required	 Doses over 100mg/day may be given under specialist advice. Better for agitation due to delirium.
	Subcutaneous infusion	Start with 50mg over 24h (can be given as bd injections)	 Consider using lower doses in elderly patients.
Haloperidol Use where levomepromazine is not available.	Subcutaneous injection	1mg every 2 hours as required.	
	Subcutaneous infusion	Start with 5 to 10mg over 24h	




 https://www.gov.scot/publication s/coronavirus-covid-19-palliativecare-toolkit/



 https://www.palliativecareguideli nes.scot.nhs.uk/guidelines/sympt om-control/alternatives-toregular-medication-normallygiven-via-a-syringe-pump-whenthis-is-not-available.aspx







- Undisturbed
- Check they are able to speak, who is there
- Warning shot
- Check understanding
- What will you do now? Shall we make a plan together? Are there other people you need to tell? Who is there to support you?
- Acknowledge sadness and difficulty of the situation



- Increased use for outpatient/ CNS follow up
- Family meetings
- Loss of doorstep conversations
- Still need for FTF assessmentelderly no one to assist with technology/ hard of hearing/ need to see what is going on in home
- Hospices developing virtual services e.g. breathlessness management, counselling, bereavement support




79 metastatic breast cancer

Fungating breast ca

Increased pain

Admitted for symptom control - deteriorated over admission

AF with reduced saturations, treated for wound infection



Discharge delayed as tested for COVID

- Febrile 24 hrs prior to discharge
- Tested positive COVID 19 (Friday)
- Husband distressed 'I just want my wife back'
- HSCP, DN, GP informed
- Syringe driver medication, just in case meds. Community Kardex, VOED form
- Discharged home

Disaster!

- Carers refused to visit because of COVID positive status
- Support from DN and Marie Curie Fast Track over weekend
- Family not leaving room
- House crowded with relatives
- Difficulty complying with social distancing
- Pain uncontrolled
- Emergency readmission following the weekend

Re-admitted for end of life care

- Husband unable to visit on readmission
- Staff with her when she died
- Distressing for everyone

Learning

- Early in pandemic-first COVID positive patient for community staff involved
- Less control over family behaviour in community setting (social distancing/ handwashing)
- Moral distress re visiting restrictions
- No PPE available for informal carers at that point

Useful links informal carers

- <u>Scottish Government Website Coronavirus (COVID-19) unpaid carers providing personal care</u>. Information on this website of where to get PPE and who would require it. Social Care PPE Support Centre on 0300 303 3020
- Just in case medication
- Caring for patients in last days of life
- https://helixcentre.com/ content-img/projects/eolc-toolkit/Practical-Care-For-Dying-Person-Toolkit.pdf
- NHSGGC Booklet What can happen when someone is dying
- NHS Inform Palliative Care
- NHSGGC Palliative Care Symptom Control

NHSGGC Bereavement Information and Support

References

- Keeley P, Buchanan D, Carolan C, Pivodic L, Tavabie S, Noble S. Symptom burden and clinical profile of COVID-19 deaths: a rapid systematic review and evidence summary. BMJ supportive & palliative care. 2020;28:28.
- Sese D, Makhoul A, Hoeksema L, Shoemaker L. The role of palliative care in COVID-19.
 Cleve Clin J Med. 2020;29:29.
- Sutherland AE, Stickland J, Wee B. Can video consultations replace face-to-face interviews? Palliative medicine and the Covid-19 pandemic: rapid review. BMJ supportive & palliative care. 2020;26:26.



- How can we support end of life care at home for COVID positive patients who do not wish hospital admission
- How do we support those dying following delayed diagnosis or who have not been able to receive treatment e.g. palliative chemotherapy due to COVID
- Bereavement support for families who have not been able to be with loved ones, experience usual rituals around funerals etc